Sysmex, Eisai Team Up For Alzheimer’s Diagnostics
Executive Summary
Sysmex is teaming up with fellow Japanese pharma company Eisai to develop a new generation of diagnostic reagents for dementia, including Alzheimer’s disease, which is projected to affect an estimated 65.7 million people globally by 2030 according to the World Health Organization. The companies have entered into a non-exclusive collaboration to create novel IVD products that will enable early detection as well as help physicians in treatment selection and effectiveness monitoring.
You may also be interested in...
Alzheimer’s Disease: Moving Toward The Era Of Diagnostic Certainty
With more than 13 million people in the US expected to have Alzheimer’s disease (AD) by 2050, an increasing number of companies are focused on developing reliable AD diagnostics designed to facilitate early detection and treatment. Although the field remains in its relative infancy, researchers are gaining greater diagnostic certainty through a combination of diagnostic approaches, and over the next decade, the AD diagnostics market is projected to reach a US market value of at least $1 billion to $3 billion per year.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.